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Estrogenic Activity of Glycitein, a Soy Isoflavone
Tong T. Song, Suzanne Hendrich, and Patricia A. Murphy*
Food Science and Human Nutrition, 2312 Food Sciences Building, Iowa State University,
Ames, Iowa 50011
Glycitein (4′,7-dihydroxy-6-methoxyisoflavone) accounts for 5-10% of the total isoflavones in soy
food products. The biological activity of this compound has not been reported to date, although
numerous studies have been performed with the other soy isoflavones, daidzein and genistein.
Glycitein was isolated from soy germ to 99% purity. Weaning female B6D2F1 mice were dosed with
glycitein (3 mg/day), genistein (3 mg/day), and diethylstilbestrol (DES) (0.03 íg/day) in 5% Tween
80 by gavage for 4 days. A control group received an equal volume of 5% Tween 80 solution daily.
The uterine weight increased 150% with glycitein (p < 0.001), 50% with genistein (p < 0.001), and
60% with DES (p < 0.001) compared with the control group. DES, 17â-estradiol, and three isoflavones
(daidzein, genistein, and glycitein) were examined for their competitive binding abilities with 17â-
(3H)estradiol to the estrogen receptor proteins of the B6D2F1 mouse uterine cytosol. The
concentrations of each compound required to displace 50% of the (3H)estradiol at 5 nM in the
competitive binding assay were 1.15 nM DES, 1.09 nM 17â-estradiol, 0.22 íM genistein, 4.00 íM
daidzein, and 3.94 íM glycitein. These data indicated that glycitein has weak estrogenic activity,
comparable to that of the other soy isoflavones but much lower than that of DES and 17â-estradiol.
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INTRODUCTION
Estrogens play important hormonal roles among all
vertebrates. Animal estrogens are exclusively steroidal
compounds, and the principal physiological estrogen in
most species is 17â-estradiol. Many plants produce
compounds that possess estrogenic activity in animals
and are, thus, called phytoestrogens. These compounds
have some structural similarity to the mammalian
estrogen, 17â-estradiol. A common structural charac-
teristic of many of these compounds is the presence of
a phenolic ring, a prerequisite for the binding to the
estrogen receptor (Figure 1).
Soybeans contain the highest concentrations of isofla-
vones, at 1-3 mg/g, as daidzein, genistein, glycitein, and
their corresponding glucosides, of foods consumed by
humans. These soy isoflavones may have some impor-
tant health-enhancing properties such as prevention of
certain cancers (Barnes et al., 1991), lowering the risk
of cardiovascular diseases (Anderson et al., 1995), and
improvement of bone health (Bahram et al., 1996). Their
estrogenic activities may play an important role in their
health-enhancing properties. Genistein and daidzein
account for the major portion of isoflavones in soy foods
and have been the focus of numerous studies. The
estrogenic activities of daidzein, genistein, and their
glucoside forms, genistin and daidzin, were 100000-
500000 times lower than that of diethylstilbestrol (DES)
as assessed by the mouse uterotropic assay (Farmaka-
lidis and Murphy, 1985). Estrogen receptor binding
studies with soy isoflavones, genistein and daidzein,
demonstrated they had the abilities to bind to estrogen
receptors from different species including mice, rats, and
sheep (Verdeal et al., 1980). No biological studies on
glycitein have been reported to date. However, glycitein
accounts for 5-10% of the total isoflavones in soy foods
and may be as high as 40% in some soy supplements
composed of soy germ (Song et al., 1998; Tsukamoto et
al., 1995). Therefore, it is important to evaluate the
biological activity of glycitein. Because glycitein has a
structure similar to those of genistein and daidzein, we
hypothesize that it will have estrogenic activity.
There are a number of methods to assess estrogenic
activity. Reel et al. (1996) proposed a test array for
potential estrogenic activity. These methods can be
grouped into four categories: (1) estrogen receptor
binding; (2) estrogen receptor-dependent transcriptional
expression; (3) reproductive tract response; and (4)
nonreproductive tract target tissue response. It is
preferable to perform more than one assay to confirm
the results. The binding affinities of soybean isoflavones
were much lower than those of estradiol and DES
(Verdeal et al., 1980). Farmakalidis and Murphy (1985)
evaluated the estrogenic activity of genistin and daidzin,
the isoflavone glucosides, and showed that the gluco-
sides had estrogenic activity equal to that of the
aglycons on a molar basis. The mouse uterine enlarge-
ment assay has been the standard in vivo method to
evaluate estrogenic activity (Bickoff et al., 1962), and,
because it is performed in an intact animal, the effects
of absorption, metabolism, serum binding, and phar-
macokinetics are taken into account. These two methods
were used to establish the estrogenic activity of gly-
citein.
MATERIALS AND METHODS
Chemicals. DES, Tween 80, 17â-(2,4-3H)estradiol (23 mCi/
mmol), 17â-estradiol, and dextran-coated charcoal (DCC) were
obtained from Sigma Chemical Co. (St. Louis, MO). ACS
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scintillation fluid was purchased from Fisher Scientific Inc.
Glycitein was purified according to the following method: 10
g of soygerm (generously donated by Schouten USA, Inc.,
Minneapolis, MN) was hydrolyzed in 100 mL of 0.1 N HCl at
98 °C for 2 h, extracted with acetonitrile, and filtered through
Whatman No. 42 filter paper. The filtrate was dried by a rotary
evaporator at 50 °C. The residue was dissolved in 80% ethanol
and applied to a Sephadex LH-20 column (2.5 cm  50 cm)
with 50% ethanol as the eluent. The glycitein peak was
collected and freeze-dried. Genistein was purified from soy-
beans using the same procedure as glycitein. Daidzein was
chemically synthesized according to the method of Song et al.
(1998). The identification and purity of glycitein, daidzein, and
genistein were confirmed by HPLC, ultraviolet (UV) spectral
analysis, melting point, and mass spectrum analysis. Glycitein,
daidzein, and genistein were analyzed by HPLC on a Beckman
System Gold chromatography system consisting of a model 507
autosampler, a model 126 dual pump, a model 168 photodiode
array detector, and an IBM 486 computer with Beckman Gold
system HPLC data processing software (version 8, 1993)
according to the procedure of Murphy et al. (1997). A YMC-
pack ODS-AM-303 column (5 ím, 25 cm  4.6 mm) (YMC Inc.,
Wilmington, NC) was used. UV spectral analysis was per-
formed according to the method of Mabry et al. (1970) using a
Beckman DU 7400 spectrophotometer. The melting point was
measured with a Perkin-Elmer 7 series differential scanning
calorimeter (DSC) (Perkin-Elmer Inc., Norwalk, CT). Mass
spectrum analysis using direct probe introduction and chemi-
cal ionization was performed on a Finnigan model TSQ-700
mass spectrometer (Finningan Inc., Piscataway, NJ).
Animals and Treatments. The mice uterine enlargement
assay was performed according to the method of Farmakalidis
and Murphy (1985). Inbred B6D2F1 mice were obtained from
Harlan Sprague-Dawley (Madison, WI). Each dam was
housed separately with her female pups (14 days old on
arrival), and the mice received AIN-93 M diet (Reeves et al.,
1993) and water. Pups were weaned at 21 days of age. The
mice were randomly assigned to treatment groups (control,
DES, genistein, and glycitein) of 20 mice per group. An AIN
93-G diet and water were provided. This semipurified diet
contained no soy isoflavones by our HPLC analysis (Song et
al., 1998). Genistein, DES, and glycitein were suspended in
5% Tween 80 and were administered to the mice by gavage
needle in four daily doses of 0.1 mL suspension/day beginning
on the day after weaning for 4 days. The total doses were 0.12
íg of DES/mouse or 12 mg of genistein or glycitein/mouse. The
control group was given 0.1 mL of 5% Tween 80 for 4 days. At
24 h after the last dose, mice were weighed and sacrificed
under CO2. Their uteri were dissected out, and the wet weights
were obtained immediately. Mouse uteri were homogenized,
and cytosols were prepared for estrogen receptor binding assay
as described below. The blood from genistein and glycitein
groups was collected by using cardiac puncture. Plasma was
prepared by centrifugation at 5000g for 10 min at 4 °C and
kept frozen until analysis of plasma isoflavones. The animal
experimental protocol was approved by Iowa State University
Animal Use Committee.
Tissue Handling and Estrogen Receptor Assay. The
estrogen-binding assay was modified from the procedure of
Verdeal et al. (1980). Mouse uteri were homogenized (Brink-
mann Instruments, Rexdale, ON, Canada) in 10 mM Tris and
1 mM EDTA, pH 7.4, buffer (1:10 w/v). The cytosol fractions
were obtained by centrifugation of the homogenate at 100000g
for 1 h. Total binding was determined by adding 0.2 mL each
of 1 mM EDTA, pH 7.4, buffer, (3H)estradiol (1.5 ng/mL in 1
mM EDTA pH 7.4 buffer), and cytosol fraction. Nonspecific
binding was determined by replacing the 1 mM EDTA buffer
with 0.2 mL of 17â-estradiol (1500 ng/mL in the 1 mM EDTA,
pH 7.4, buffer). Blanks contained 0.4 mL of 1 mM EDTA buffer
and 0.2 mL of (3H)estradiol. Competitive binding was deter-
mined by replacing the 0.2 mL of buffer in the total binding
mixture with 0.2 mL of solution containing the different
estrogens at appropriate concentrations in 1 mM EDTA, pH
7.4, buffer. Duplicates were performed for each estrogen at
each concentration. Samples were incubated at room temper-
ature (23 °C) for 2 h. DCC (2.5%, 0.5 mL) in 1 mM EDTA buffer
was added to all mixtures after incubation. The samples were
mixed, incubated for 15 min, and centrifuged at 1000g for 10
min. After centrifugation, the supernatants were decanted into
scintillation vials containing 10 mL of ACS scintillation fluid.
The samples were counted for 10 min on a Packard liquid
scintillation analyzer model 1900TR (Packard Instrument Co.,
Downers Grove, IL).
Plasma Isoflavone Analysis. Plasma samples of the
genistein group and the glycitein group were combined to give
one pooled sample for each treatment. Two milliliters of 0.2
M sodium acetate, pH 5.5, buffer, 100 íL of â-glucouronidase/
sulfatase (Sigma Chemical Co.), and 20 íL of 4 mg/mL internal
standard, 2,4,4′-trihydroxydeoxybenzoin (THB) (Song et al.,
1998), were added to 2 mL of plasma sample. The mixture was
incubated at 37 °C for 16 h. Six milliliters of methanol was
added to the mixture, mixed well, and centrifuged at 10000g
for 20 min. Eight milliliters of supernatant was brought to
dryness and dissolved in 400 íL of 80% methanol. After
centrifugation, 20 íL of sample was taken for isoflavone
analysis by our HPLC system. The HPLC conditions were the
same as in the identification of genistein and glycitein stated
above. The minimal detection level by UV detector at 254 nm
for genistein and glycitein was 0.5 íg/mL or 1.9 íM in injection
solution.
Statistical Analysis. The uterine enlargement data were
analyzed by using a one-way classification analysis of a
completely randomized design (SAS version 6, SAS Institute
Inc., Cary, NC) at R ) 0.05.
Figure 1. Chemical structures of soy isoflavones, 17â-estradiol, and DES.
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RESULTS AND DISCUSSION
The purity of glycitein and genistein was confirmed
by HPLC, UV spectral analysis, melting point, and mass
spectrum analysis. The HPLC chromatography of gly-
citein showed one single peak. The purity of glycitein
was confirmed by peak area percentage and peak purity
program to be >99%. Naim et al. (1973) first isolated
glycitein from soybeans and reported UV spectral data
of glycitein. The UV spectral data for our glycitein were
ìmax (methanol) 257 ( ) 31622), 319 nm; ìmax (sodium
methoxide) 259, 344 nm; ìmax (AlCl 3) 257, 317 nm; ìmax
(AlCl 3 - HCl) 257, 317 nm; ìmax (sodium acetate) 255,
346 nm; and ìmax (sodium acetate/H3BO3) 255, 320 nm.
These data were the same as reported by Naim et al.
(1973). The molecular weight of our glycitein from the
mass spectrum analysis was 284, which matched the
mass reported by Naim et al. (1973) and the calculated
molecular weight of glycitein. The melting point of
glycitein measured by DSC was 337-339 °C and gave
a very sharp thermogram. This melting point differed
from that reported by Naim et al. (1973) of 311-313 °C
and that reported by Kelly et al. (1993) of 290 °C (dec).
Recently, Nogradi and Szollosy (1996) chemically syn-
thesized glycitein and reported a melting point of 337-
339 °C. The purity of genistein was confirmed to be
>99% by using the similar method for glycitein.
In a preliminary study, we used chemically synthe-
sized genistein (Chang et al., 1994) as one of the positive
controls and did not obtain any estrogenic response from
the mice uterine enlargement assay. However, estro-
genic responses from glycitein and DES were apparent.
We evaluated the purity of the synthesized genistein
and found that it contained a contaminant coeluting in
our analytical HPLC system with authentic genistein.
A broad melting point thermogram indicating a mixture
of genistein and the contaminant was detected by DSC
analysis. To avoid this problem, we purified the genistein
from soybeans for the present study.
The uterine enlargement assay yielded significant
differences (p < 0.001) in uterine weights among treat-
ments (Table 1). The glycitein, genistein, and DES
groups had 150, 50, and 60% greater uterine weight,
respectively, compared with the control. The relative
estrogenic potencies of DES, genistein, and glycitein
were 100000, 1, and 3, respectively (Table 1). The
relative estrogenic potencies of DES, glycitein, and
genistein were estimated on the basis of the doses
required to produce the same increase of uterine weights.
The relative estrogenic potencies of genistein and DES
from the present study were similar to the results of
Farmakalidis and Murphy (1985), who found the rela-
tive molar potencies of DES, genistein, genistin, and
daidzin to be 100000, 1, 1, and 0.26, respectively. The
present study demonstrated that the estrogenic potency
of glycitein in mice uterine enlargement assay was 3
times higher than that of genistein, but, as hypoth-
esized, was much lower than that of DES.
It is generally considered that nonsteroidal estrogens
exert their stimulatory effect on the estrogen receptor
by binding to the same site as that occupied by steroidal
estrogens such as 17â-estradiol. Our competitive binding
study results are shown in Figure 2, in which increasing
concentrations of unlabeled competitors displace bound
(3H)estradiol. These results confirm that glycitein has
the ability to bind to the estrogen receptor. DES had a
much higher binding affinity compared with that of the
three isoflavones. The relative affinities of these com-
pounds for the mice estrogen receptor were calculated
by dividing the CB50 of unlabeled 17â-estradiol by the
CB50 of a competitor and then multiplying by 100 (Table
2). These data, once again, confirmed that both DES and
estradiol had a much greater binding affinity to estrogen
receptor than the three isoflavones. Among the three
soybean isoflavones, genistein had the greatest estrogen
receptor binding affinity. The in vitro estrogen receptor
binding data in this study were comparable to the
previous results summarized by Verdeal et al. (1980).
They reported that genistein had a binding affinity
roughly 100 times lower than that of 17â-estradiol, and
daidzein had a binding affinity 10-15 times lower than
that of genistein.
The plasma extraction and analysis recovery was 85%
for internal standard THB. The recovery-corrected
plasma isoflavone concentrations for genistein-treated
and glycitein-treated group pooled sample were 0.42 and
0.72 íM, respectively. Xu et al. (1994) and King et al.
(1995) have reported in humans and in rats that 4-6 h
after isoflavone dosing, daidzein and genistein reached
maximal concentrations in plasma and then decreased
thereafter. At 24 h after dosing, there were only trace
concentrations of daidzein and genistein in the plasmas.
Because we collected blood 24 h after the last dose of
isoflavones, the low plasma isoflavone concentrations
may be the result of rapid metabolism or excretion of
isoflavones after dosing.
Table 1. Estrogenic Activities of Soy Isoflavones in Mice
treatment
body wt (g)
estrogen
total
dose
no. of
mice
uterine wta (mg,
mean ( SEM initial final
relative
potencyb
control 0 mg 20 17.7 ( 0.9c 8.1 11.6
DES 12 íg 20 28.5 ( 1.1b 8.1 11.7 100000
glycitein 12 mg 20 44.6 ( 3.1a 8.3 12.1 3
genistein 12 mg 20 26.4 ( 1.0b 8.2 11.7 1
a Uterine weight means bearing different letters are signifi-
cantly different, p < 0.05. b The relative potency was calculated
on the basis of the doses of estrogen required to produce a 10-mg
increase of uterine weight.
Figure 2. Competitive binding analysis of isoflavones. Cytosol
from mouse uteri was incubated with 1.5 ng/mL 17â-(3H)-
estradiol in the presence of increasing concentrations of
unlabeled estrogens. n ) 2.
Table 2. Relative Affinities of Estrogens for Estrogen
Receptorsa
compound CB50 (íM) relative affinity
17â-estradiol 0.00109 100
DES 0.00115 95
genistein 0.223 0.49
daidzein 4.00 0.027
glycitein 3.94 0.028
a Based on the molar concentrations (CB50) required to displace
50% of the (3H) estradiol. n ) 2.
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Glycitein gave a much lower in vitro binding affinity
compared to genistein in the estrogen receptor-binding
assay. However, it gave higher estrogenic response in
the in vivo mouse uterine enlargement assay. This may
be the result of a higher bioavailability of glycitein
compared to that of genistein in mice. In a human
isoflavone metabolic study, a higher bioavailability of
glycitein compared with that of genistein was demon-
strated (Zhang et al., 1999). Shutt et al. (1970) reported
that genistein could be metabolized to p-ethylphenol,
which is not an estrogenic compound. It may be possible
that glycitein is metabolized to compounds with greater
estrogenic potency than that of glycitein.
Daidzein has been reported to be a less effective
estrogen than genistein when fed to mice (Bickoff et al.,
1962). Our present study demonstrated that glycitein
is a stronger estrogen in mice uterine enlargement assay
compared to genistein. Of the three soy isoflavone
aglycons, it appears that glycitein has the highest
estrogenic potency in the in vivo estrogen assay.
This study has demonstrated the in vivo estrogenic
activity and the in vitro binding affinity to estrogen
receptors of glycitein. These data reveal that, although
glycitein accounts for 10% of the total isoflavones in
soy foods, its biological potency is comparable to those
of the other soy isoflavones. Development of soybean and
soy food isoflavone databases needs to include glycitein
and its glucosides. Additionally, the biological activity
of glycitein and its glucosides in humans needs to be
explored.
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